Published on
May 30, 2017
- 11:30 GMT
Cellceutix Anti-Cancer Drug Candidate’s p53 Activity in Acute Myeloid Leukemia to be Presented by Independent Researchers at the ...
BEVERLY, Mass., May 30, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), is pleased to share further data supporting the p53 mechanism of action of Kevetrin and its treatment potential in Acute Myeloid Leukemia (AML) at the …
Distribution channels:
Technology
